Platform · Ingredient Engine
Each stage has to earn the next
The Ingredient Engine is EUTECNIQ’s proposed development system: eight stages from candidate selection and sourcing to a commercial route. Regulatory and economic feasibility is screened at intake and screened again whenever the material, process, formulation or intended use changes.
The engine shows how EUTECNIQ would decide: which technology to use, which alternatives fail, what evidence is missing and when to stop.
Proposed capabilityCompany in formation (what exists today). Every stage here is a proposal; rules and published evidence are cited in each stage.
The engine at a glance
- 8
- stages, from candidate to commercial route
- 1
- feasibility screen, run at intake and again on every change of material, process, formulation or intended use
- 3
- outcomes at every gate: progress, repeat or stop
- 4
- routes to value: a client program, a license, supply or a partnered drug program
01 · The engine
Every stage ends in a decision to progress, repeat or stop
One workspace: the eight stages, with one worked program running on them. Change a decision of the turmeric-extract program, and the diagram marks which stages stay settled, reopen or reject it. Select a stage to see that program’s decision, the alternatives turned down, the physical and commercial consequence and the evidence still missing, above the stage’s general method. The band above the stages is the feasibility screen, which runs again whenever the material, process, formulation or intended use changes.
SettledReopenedRejected Hypothetical program Values from the studies cited on Demonstration 4; the reopen and reject rules are decisions argued there, not regulatory requirements.
- 0Intake and screen
- 1Discover and prioritize
- 2Authenticate the source
- 3Extract and optimize
- 4Characterize and standardize
- 5Engineer delivery
- 6Safety and performance
- 7Scale and transfer
- 8Commercialize
- Progress through a gate
- Repeat an earlier stage
- Re-screen after a change
- Document produced
Proposed capability Eight proposed stages. The dashed rail is the feasibility screen: it starts at intake, and a marked stage sends the program back to it when that stage changes the material, process, formulation or intended use. Select a stage to open its detail.
0Intake and the regulatory and economic feasibility screen
Is there a lawful route for the intended use, and can its evidence be produced at a cost the product can carry?
The problem it solves
Intended use decides the U.S. category: dietary supplement, food, cosmetic or drug. The category fixes the safety standard, the evidence worth producing and the document that closes the work. Found late, the answer can leave finished work in the wrong category or priced out of its market.
What is screened
- Regulatory. The category implied by the intended use and claims; whether the ingredient is a new dietary ingredient, which needs a notification at least 75 days before marketing unless the food-supply exception applies; conservation, import and access rules; the drug path where a therapeutic signal exists.
- Economic. The cost of the evidence the route needs, the process cost drivers and the margin the market would support.
How alternatives are selected
The route chosen is the one whose evidence can be produced at an acceptable cost. Stop criteria are written before the work starts. Counsel reviews any conclusion that is a legal question.
What is recorded
Intended use and target markets, the category hypothesis and route, the evidence list with a cost range, and the stop criteria.
What it produces
A dated feasibility screen record. FDA does not approve dietary supplements or NDI notifications, so the record states the route and its document, never an approval.
Commercial value
It is the cheapest decision in the program, and it guards against the most expensive mistake: finishing development in a category the product cannot lawfully enter. Evidence costs are large enough to decide a program. In EU contract-laboratory quotes from 2010 to 2018, one carcinogenicity study cost about €700,000.
Published evidence What each kind of change sends back to the screen. Rules as of October 2026; not legal advice.
| Change | Usually at | Re-checked | Rule or source |
|---|---|---|---|
| Material: species, plant part, origin or supplier | Stage 2 | Identity and new-dietary-ingredient status; conservation and access terms; contaminant profile; supply cost and security | Identity in an NDI notification starts with the Latin binomial name, including the author (21 CFR 190.6(b)(2)); CITES; Nagoya Protocol |
| Process: solvent, concentration or purification step, scale or site | Stages 3 and 7 | Whether the extract is still the same ingredient; residual-solvent class; comparability with earlier lots; cost of goods | When a notification is required, including what “chemically altered” means, is still addressed only in FDA’s 2016 revised draft guidance (FDA 2016); ICH Q3C(R9); comparability logic of ICH Q5E |
| Formulation: carrier, particle size or dosage form | Stage 5 | The safety case for the new form; the excipients’ status in the category; whether the form stays in the category; the cost of new studies | For a nanoscale form, FDA states that data on the conventional form alone are unlikely to address its safety (FDA NDI guidance, October 2026); sublingual products “are not dietary supplements and are not foods” (FDA warning letter, February 5, 2019) |
| Intended use: claims, population, dose or market | Stages 6 and 8 | The category; the studies needed; whether a drug path opens; the cost of the new evidence | Articles intended to diagnose, cure, mitigate, treat or prevent disease are drugs (21 U.S.C. 321(g)(1)); structure/function statements (21 CFR 101.93); reproductive and developmental data recommended when a product is intended for use in pregnancy, lactation or young children (FDA NDI guidance); an IND for studies of disease endpoints (21 CFR Part 312) |
Progress when
A lawful route exists for the intended use, and its evidence can be produced at an acceptable cost.
Repeat when
The material, process, formulation or intended use changes at any later stage (table above).
Stop when
The intended use falls outside every lawful channel, or the evidence would cost more than the commercial case can carry.
Go deeper Regulatory overview · NDI notifications · Legal status and counsel · The four named gates
Sources: 21 U.S.C. 321; 21 CFR 190.6; FDA NDI guidance (October 2026); Meigs et al., ALTEX 2018, Table 3 (third-party estimate; EU prices, probably below 2026 levels). Stop criteria and the screen record are EUTECNIQ proposals.
1Discover and prioritize
Which candidates deserve laboratory time, and on what evidence?
The problem it solves
Candidates are many; plant material, instrument time and money are scarce. Kew counted 25,791 documented medicinal plant species in 2020, and of 5,411 assessed for extinction risk, 723 (13%) were threatened. Most candidates have to be dropped before the bench, and sourcing is screened from the start.
Technologies evaluated
- Literature, database and traditional-use review; traditional use is one possible starting evidence and is not clinical proof
- Computed molecular descriptors checked against published rules, such as Lipinski’s rule of five
- Bioactivity-guided fractionation, with dereplication to drop known compounds early
- LC-HRMS and molecular networking of MS/MS spectra (GNPS)
How alternatives are selected
Candidates are ranked on their starting evidence, the intended use and its category, whether a lawful and sustainable source exists, and a first estimate of the evidence cost. A model may rank candidates; its ranking would inform a decision only after its error has been measured on botanicals it never saw.
What is measured
Where a program traces its actives: the activity of each fraction, and accurate mass and fragments of the active constituents. For every candidate: the access and conservation status of the source. Computed properties are recorded as predictions.
What it produces
A candidate dossier with sources and access status, an active-constituent map with draft markers, and a draft target product profile: intended use, category, format and the claims the evidence would have to support.
Commercial value
Stopping a weak candidate while the answer costs a literature search, instead of a pilot campaign, is the cheapest saving in the program. The dossier is the basis of a scoped development proposal.
Progress when
The candidate has documented starting evidence, a category hypothesis and a source that can be qualified.
Repeat when
New evidence, or a changed intended use, re-ranks the list.
Stop when
There is no documented starting evidence, the species is threatened without a sustainable source, access terms cannot be agreed, or activity disappears on fractionation or traces to a known toxicant.
Go deeper Discovery and characterization · How a model would be judged · Scientific Intelligence program · Computational research on curcumin, quercetin and berberine · Candidates and their actives
Sources: Royal Botanic Gardens, Kew 2020; Lipinski et al. 2001; Wang et al. 2016 (GNPS). Ranking criteria are EUTECNIQ proposals.
2Authenticate and qualify the source
Is the material what the supplier says it is, and can it be supplied consistently and lawfully?
The problem it solves
A supplier’s certificate of analysis does not establish identity. A supplement manufacturer must verify the identity of every dietary ingredient by at least one appropriate test or examination before use (21 CFR 111.75(a)(1)(i)). Wrong species, wrong plant part, adulteration and lot-to-lot variability all start here.
Technologies evaluated
- Macroscopy and microscopy of crude material
- HPTLC fingerprint against authenticated reference material (USP ⟨203⟩; see also ⟨563⟩)
- HPLC or LC-MS marker profile, and targeted tests for known adulterants
- DNA barcoding of crude material, through partners
- Stable isotope ratios, where a synthetic substitute copies the natural profile
- Supplier audit and verification of certificates against independent results
How alternatives are selected
Methods are combined so that each is blind to something the others see. Processing removes visual and DNA evidence, so extracts depend on chemistry, and DNA methods are used together with chemical methods. Two orthogonal methods agreeing with an authenticated reference would be EUTECNIQ’s internal standard; the rule requires at least one.
What is measured
Identity on several lots by independent methods; the lot-to-lot spread of a few marker attributes; screens for known adulterants and gross contamination; the completeness of origin, harvest and processing records. In one published set of 27 curcuminoid samples, HPLC could not tell synthetic from natural material, and isotope ratios could.
What it produces
An ingredient identity passport; a supplier qualification file with approved specifications; and, for imported material, an import file with permits, prior notices, foreign supplier verification records and access agreements.
Commercial value
Specification, identity and quality-control rules accounted for about half of FDA’s Part 111 citations each year, FY2019–FY2025. A qualified source with an identity passport answers the first questions a buyer or an inspector asks, and secures supply before money goes into process work.
Progress when
Two orthogonal methods agree with an authenticated reference, adulterant screens are negative, and several documented lots are available.
Repeat when
A new supplier, origin or plant part is proposed, or stage 3 traces variability to the raw material. Either also re-runs the feasibility screen.
Stop when
The species or plant part is wrong, an adulterant is found, no authenticated reference exists, the supplier cannot be audited, or a required permit or access agreement is missing.
Go deeper Fingerprint and isotope data · Analytical characterization · Traceable supply chain · Global ingredients · USP, ICH and COA
Sources: 21 CFR Part 111; USP general chapters; Raclariu et al. 2018; Perini et al. 2023; FDA inspection observations, FY2019–FY2025; 21 CFR Part 1, Subpart L; CITES; Nagoya Protocol.
3Extract, separate and optimize
Which process gets the actives out at a defined composition, with an acceptable residue and cost?
The problem it solves
Yield, purity and recovery are three different numbers tied by one mass balance: yield × purity = recovery × the target’s content in the feed. A process tuned for yield can dilute the target. A laboratory yield is also not a plant cost: solvent-to-feed ratio, the energy to recover solvent, cycle time, downstream purification and the solvent’s fire class decide the cost per kilogram.
Technologies evaluated
- Maceration and percolation; ultrasound- and microwave-assisted extraction; pressurized liquids
- Supercritical CO₂, with or without a co-solvent; subcritical water
- Purification by adsorbent resins, membranes, liquid–liquid partition, preparative and countercurrent chromatography, and molecular distillation
How alternatives are selected
The molecule (polarity, heat sensitivity), the residue the category tolerates and the intended scale narrow the methods first. Water and CO₂ are the reference solvents; FDA affirms CO₂ as GRAS with no limit beyond good manufacturing practice. Designed experiments then map solvent, temperature, ratio and particle size against yield, purity and solvent use. Where these goals conflict, the set of best compromises (a Pareto front) is compared with the specification and the cost target.
What is measured
Extract yield; recovery and purity of the target constituents; degradation products; residual solvent against its ICH Q3C class; solvent-to-feed ratio and solvent recovered; closure of the mass balance.
What it produces
A process description with set points and ranges, a laboratory design space, a closed mass balance and extract lots for characterization at stage 4.
Commercial value
A process that holds composition can be transferred or licensed. Processes can be patent-eligible, while a naturally occurring constituent is not eligible merely because it has been isolated. Solvent recovery usually sizes the plant: the illustrative ethanol train on the process engineering page charges 8 kg of solvent per kilogram of herb.
Progress when
The process gives the target composition repeatably at laboratory scale, the mass balance closes and the residue fits the category.
Repeat when
Variability traced to the raw material returns the program to stage 2; a specification that stage 4 cannot meet, or attributes that drift at stage 7, return it here. A new solvent or concentration step can raise the question whether the extract is a new dietary ingredient, so it re-runs the screen.
Stop when
The content cannot be held within a defined range, the solvent or its residue is unacceptable for the category, or the projected cost of goods exceeds what the market supports.
Go deeper Extraction and purification · Purification and standardization · Process engineering Demo Extraction
Sources: ICH Q3C(R9); 21 CFR 184.1240; Association for Molecular Pathology v. Myriad Genetics (2013); FDA revised draft NDI guidance (2016). The mass balance is an identity; the solvent charge is an illustrative input, not plant data.
4Characterize and standardize
What is in the material, how much does it vary, and can every specification be measured reliably?
The problem it solves
An extract can contain hundreds of compounds, and one species can carry different chemistries: Thymus vulgaris alone has six chemotypes. Climate, harvest and drying shift the profile further. A specification has to be built from lot data, every limit needs a method shown to be fit for purpose, and a targeted method finds only what it looks for.
Technologies evaluated
- UHPLC with diode-array detection; LC-MS/MS; high-resolution LC-MS for non-targeted screening
- HPTLC and chromatographic fingerprints compared by chemometrics (statistics that compare whole profiles)
- GC-MS; ICP-MS for elements; compendial microbiology; NMR through partners
How alternatives are selected
Each attribute gets the method that answers its question: targeted assays for named markers and contaminants, non-targeted screening for adulterants and unknowns. The extract type decides what is controlled; the European Medicines Agency distinguishes standardized, quantified and other extracts. Markers are chosen for control, whether or not they cause any effect.
What is measured
Marker and active content; fingerprint similarity to reference lots; elemental impurities, pesticide residues, residual solvents, mycotoxins and microbial counts; moisture and particle size; the spread between lots.
What it produces
A specification with a reason for each limit, methods validated under ICH Q2(R2) with their reports, a certificate-of-analysis format and a characterization package. For supplements the legal test is a scientifically valid method (21 CFR 111.75(h)(1)).
Commercial value
The specification and its certificate of analysis are what a buyer qualifies and what an inspector reads first. Lot-to-lot consistency, shown with data, is the basis of a standardized ingredient that can carry its own name.
Progress when
Every attribute has a fit-for-purpose method, composition falls in a range that can be justified, and contaminants are below the proposed limits.
Repeat when
Marker variability is too wide to standardize: the program returns to stage 3 for the process or stage 2 for the source. A constituent of concern re-opens the safety assessment of stage 6.
Stop when
A contaminant exceeds its limit with no practical removal step, no fit-for-purpose method exists for a critical attribute, or an adulterant or unexplained major constituent appears.
Go deeper Analytical characterization · Method development · Purification and standardization · Targeted and non-targeted analysis Demo Consistency
Sources: Thompson et al. 2003; EMA reflection paper on extract types (2010); EMA reflection paper on markers (2008); ICH Q2(R2), FDA final guidance (2024); 21 CFR Part 111.
5Engineer delivery
Which barrier limits the active, and which carrier addresses it in the intended format?
The problem it solves
An active has to dissolve, survive storage and digestion, and cross the gut wall before it reaches the blood. Each step fails for a different physical reason, so the barrier is identified before a carrier is chosen. Higher solubility or dispersibility does not by itself mean higher absorption.
Technologies evaluated
- Lipid-based and self-emulsifying systems, classed with the lipid formulation classification system
- Nanoemulsions; phospholipid complexes; cyclodextrin inclusion complexes
- Amorphous solid dispersions; encapsulation; spray drying and freeze-drying to stable powders
How alternatives are selected
A barrier diagnosis comes first: solubility and partitioning, chemical stability and the likely absorption limit. Carrier families are then measured against limits fixed in advance, using only components lawful in the target category. If absorption is not limited by solubility or dissolution, a carrier would add cost without benefit, and none is added.
What is measured
Solubility and partitioning; droplet or particle size by dynamic light scattering (ISO 22412) and laser diffraction (ISO 13320); surface charge; encapsulation efficiency; dissolution (USP ⟨2040⟩); in vitro digestion with the INFOGEST protocol as a bioaccessibility screen; physical and chemical stability over time.
What it produces
A formulation prototype and a delivery technology dossier that states the mechanism, the measurements and what they do not show. Nanoemulsion stability is not demonstrated bioavailability, and in vitro bioaccessibility is not systemic exposure.
Commercial value
The carrier sets the format, the serving size and the evidence a product needs. A delivery system that is measured, specified and protectable can be licensed across products; its value rests on the human data of stage 6.
Progress when
The prototype meets its physical and chemical stability targets, and a stated mechanism links the carrier to the identified barrier.
Repeat when
The active degrades in the format (back to stage 3 or 4), or stage 6 finds that the format changes exposure or the safety case. A new form re-runs the screen: for a nanoscale form, FDA states that data on the conventional form alone are unlikely to address its safety.
Stop when
Absorption is not limited by solubility or dissolution, excipient levels are unsuitable for the category or dose, the system is physically or chemically unstable, or it cannot be scaled.
Go deeper Advanced delivery · Emulsions and colloids · Drying and particle engineering · Bioavailability by design Demo Solubility
Sources: Pouton 2000 and 2006; ISO 22412; ISO 13320; USP ⟨2040⟩; Brodkorb et al. 2019 (INFOGEST); FDA NDI guidance (October 2026).
6Establish safety and performance evidence
Is the ingredient safe at the intended intake, and does the product do what its design is meant to do?
The problem it solves
Safety is judged at the intended exposure, and the evidence worth producing depends on the route. No test battery is prescribed for a new dietary ingredient. FDA’s NDI guidance recommends calculating the acceptable daily intake (ADI) as the NOAEL, the highest dose without an adverse effect, divided by a safety factor. An estimated daily intake (EDI) at or below the ADI supports safety.
Technologies evaluated
- Exposure estimate from the intended use; history-of-use and literature review
- In vitro screens; studies to OECD guidelines at GLP partner laboratories (21 CFR Part 58)
- NOAEL or benchmark dose; the threshold of toxicological concern for minor constituents
- Enzyme and transporter interaction screens
- Stability studies at ICH Q1A(R2) storage conditions, as good practice
- Human pharmacokinetic studies with clinical research organizations, under IRB review (21 CFR Parts 50 and 56)
How alternatives are selected
Studies are chosen for each ingredient from its known hazards, prior human use, intended intake and regulatory route, cheapest decisive studies first. Definitive studies would go to GLP laboratories so the data could also support a later food or drug filing. A study designed to test whether a product can diagnose, cure, mitigate, treat or prevent a disease needs an IND (21 CFR Part 312).
What is measured
Estimated daily intake; NOAEL and the resulting ADI; genotoxicity; interaction signals; stability-indicating attributes over time; and, where justified, exposure in people (blood levels over time) against the plain extract.
What it produces
A safety and exposure assessment with the intake limit, study reports where studies were run, stability data and, where a notification is needed, a draft NDI notification for the client or its counsel. Stability data support a shelf life; they are not a validated shelf life (what an NDI acknowledgment means).
Commercial value
Evidence is the part of a product a competitor cannot copy from its label. It is also the largest cost: in EU contract-laboratory quotes from 2010 to 2018, a genotoxicity battery with a 90-day study cost about €140,000, which is why the screen prices the evidence before any study is placed.
Progress when
No hazard is known at the intended exposure, EDI/ADI is 1 or less, and the performance target set at stage 5 is met by the kind of evidence the intended claim needs.
Repeat when
A format that changes exposure or the safety case returns to stage 5; a constituent of concern that a specification can control returns to stage 4. A new population or claim re-runs the screen. FDA’s NDI guidance recommends reproductive and developmental data when a product is intended for use in pregnancy, lactation or young children.
Stop when
Genotoxicity appears, the NOAEL is low relative to intake, a clinically relevant interaction is found, or the testing would cost more than the commercial case can carry.
Go deeper Toxicology and exposure · NDI notifications · Clinical research · Translational research · Bioavailability by design
Sources: FDA NDI guidance (October 2026), sections VII and IX; 21 CFR 190.6; 21 CFR Part 58; 21 CFR Parts 50 and 56; 21 CFR Part 312; EFSA benchmark dose guidance (2022); EFSA TTC guidance (2019); ICH Q1A(R2); Meigs et al. 2018, Table 3 (third-party estimate).
7Scale, validate and transfer
Does a larger process make on-specification material with its critical parameters known, and can another site repeat it?
The problem it solves
The laboratory hides physics that changes at plant scale: slower heating, coarser particles, longer mixing and the cost of recovering solvent. A larger, geometrically similar tank cannot hold power per volume, tip speed and Reynolds number constant at once, so each unit operation needs its own scale-up basis.
Technologies evaluated
- Pilot extraction, evaporation, solvent recovery and pilot drying
- Mass and energy balances; designed experiments; dimensionless scale-up rules
- Quality by design: critical quality attributes (CQAs) linked to critical process parameters (CPPs), with risk ranking
- Process analytical technology, such as near-infrared monitoring of an extraction
- Transfer of analytical procedures (USP ⟨1224⟩), and comparability against criteria set in advance
How alternatives are selected
A scale-up basis is chosen for each unit operation from published practice, then tested in pilot runs. In one published spray-drying scale-up, matching the atomized droplet size still left production trials necessary, because mixing and residence time differed. The control strategy starts with extensive end-product testing and moves toward process control only as data accumulate.
What is measured
CQAs against CPPs; yield and purity together; residual solvent; heat history; batch-to-batch consistency; closure of the mass and energy balances.
What it produces
A process development and transfer package: the process with its ranges, the CQA–CPP map, specifications with validated methods, a risk assessment of equipment and scale gaps, and the records a receiving supplement site keeps under 21 CFR Part 111. After any change, a comparability package.
Commercial value
A process another qualified site can repeat is what can be licensed, placed with a contract manufacturer or run for supply. Laboratory feasibility is not commercial demonstration, and this stage is where the difference is paid for.
Progress when
Consecutive pilot batches meet the specification under a written control strategy, and every release attribute has a validated method.
Repeat when
Quality attributes drift with scale (back to stage 3), or the format fails in processing (back to stage 5). A change of process or site is compared against criteria set in advance and re-runs the screen.
Stop when
Solvent or energy use is unsafe or uneconomic, the cost of goods exceeds what the market supports, or no qualified manufacturing capacity is available.
Go deeper Technology transfer · Process engineering · QbD and control strategy · Quality system Demo Consistency
Sources: ICH Q8(R2); ICH Q9(R1); ICH Q10; ICH Q5E (written for biotechnological products; its logic applied here); USP ⟨1224⟩ (Pappa); Thybo et al. 2008; Pan et al. 2015; Yu et al. 2014; 21 CFR Part 111.
8Commercialize, license, supply or pursue drug development
Which route turns the evidence into value: a client program, a license, supply or a partnered drug program?
The problem it solves
Evidence earns nothing until someone buys, licenses or develops it, and the law constrains the route. Claims in labeling and marketing establish intended use. If an article is approved as a drug, or authorized for investigation as one with substantial clinical investigations made public, before it is marketed as a supplement or food, it cannot later be sold as a supplement (21 U.S.C. 321(ff)(3)(B)); so the route is confirmed before any public step.
Tools evaluated
- Prior-art and patent landscaping; ownership mapping under written agreements
- Freedom-to-operate review by patent counsel
- A commercial model and a supply plan
- Market-access assessment by category and country
How alternatives are selected
Each route has its own gate. A client program fits when the client owns the result under contract. A license fits when a composition, process, formulation or method of use is protectable, and supply when a specified ingredient can be made at a margin. Drug development fits only on a strong signal and only with a partner that has drug development capacity.
What is measured
The defensible difference from existing products; freedom-to-operate findings; supply security at scale; margin; and a customer’s or partner’s commitment.
What it produces
An IP and commercialization assessment; a commercial specification and certificate-of-analysis format; supply and quality agreements with a specification exhibit and change control; a technology-transfer file; or a partnering file for a drug candidate.
Commercial value
Fees come first, then ingredients, licenses and supply. Drug candidates come last, and only through partners. FDA lists four botanical products approved as drugs under the NDA and BLA pathways. Five-year new-chemical-entity exclusivity attaches only on drug approval; supplements have no data exclusivity.
Progress when
A customer or partner commits, ownership and data terms are agreed before work starts, and counsel has reviewed freedom to operate.
Repeat when
A claim needs more evidence (back to stage 6), or a new claim, market or drug use changes the intended use and re-runs the screen.
Stop when
There is no defensible difference, freedom to operate is blocked, supply cannot be secured or margins do not work. A drug program stops when no partner exists or the supplement channel is already the chosen first use.
Go deeper Scientific deliverables · Services · Legal status and counsel · Supplement or drug · Translational research
Sources: 21 U.S.C. 321(g)(1) and (ff)(3)(B); 21 CFR 101.93; Myriad (2013); FDA CDER, “What is a Botanical Drug?” (updated September 3, 2026); FDA authors, Ther Innov Regul Sci 2025; FDA, patents and exclusivity FAQ. Routes and gate criteria are EUTECNIQ proposals.
See the three ways in, the fifteen detailed steps within the stages and the four named gates
02 · The sciences inside the stages
Seven sciences, and the ingredient they lead to, each shown with its governing equation or rule
The stages say what must be decided; these say how. Each panel states its basis: an equation, a EUTECNIQ calculation, published data analyzed here, a model estimate or a proposal.
01 Physics-informed botanical intelligence
y(x) = fphys(x; θ, h(x)), 0 ≤ y ≤ Y∞
Learned models that keep their physics and their bounds: a residual alone can leave the feasible states, so constraints are enforced and violations counted.
Illustrative correction Scientific Intelligence
02 Molecular modeling and thermodynamics
ln γi = ni Σσ pi(σ) [ln ΓS(σ) − ln Γi(σ)] + ln γiSG
Solvents and co-formers screened from each molecule's surface-charge profile (COSMO-RS family), before any material is bought.
Computed by EUTECNIQ Quantum chemistry and σ-profiles
03 Precision extraction and separation
Y/Y∞ = 1 − (6/π²) Σn n−2 exp(−n²π²Dt/r²)
Particle size, time, temperature and solvent set yield and selectivity; diffusion sets how they trade off.
Computed from the equation Extraction and separation
04 SNEDDS and advanced delivery
log S0 = 0.5 − 0.01 (Tm − 25) − log P
Many botanical actives dissolve poorly; the estimate says when a carrier such as a self-nanoemulsifying system is worth testing.
Model estimate Delivery systems
05 Characterization and standardization
T² = Σk tk² / λk
A multivariate fingerprint flags a lot that is unusual against its reference set, for a confirmatory method to explain.
Published data, analyzed here Lot consistency
06 PK, PBPK and safety evidence
Fh = QH / (QH + fu·CLint)
What reaches the blood, not what is in the capsule: absorption, first pass and clearance decide exposure and its safety margin.
Computed from the equation ADME and pharmacokinetics
07 Process engineering and scale-up
E(θ) = N (Nθ)N−1 e−Nθ / (N − 1)!
Residence time, heat and mass transfer move from the bench to the plant only if their distributions are designed, not assumed.
Computed from the equation Process engineering
08 Proprietary ingredients
specification + process + exposure data → an ingredient a buyer can verify
The long-term aim: ingredients EUTECNIQ specifies, documents and owns, paid per kilogram or per license.
Proposal The value path
03 · When something changes
Change one thing and see where the program goes back
A program rarely runs straight through. Choose what changed: the trace shows where that change usually arises, sends the program back to the feasibility screen, and lists what is checked again and the rule behind it.
The material changes: back to the feasibility screen
- Usually arises at
- Stage 2, authenticate and qualify the source
- Checked again
- Identity and new-dietary-ingredient status; conservation and access terms; contaminant profile; supply cost and security.
- Rule or source
- 21 CFR 190.6(b)(2) (identity in an NDI notification); CITES; Nagoya Protocol.
Published evidence Proposed capability From the re-screen table in stage 0, where every rule is linked to its source. Rules as of October 2026; not legal advice.
04 · Work through a stage
Three demonstrations examine single stages (extraction, consistency, solubility), a fourth follows one program through every stage, and a decision tree covers the intake screen
Each demonstration takes one question from the engine and lets you change the inputs. They are educational models with stated assumptions, not results for any ingredient.
Decision tree · Stage 0Supplement or medicine?Answer nine questions about one botanical and watch eight gates, in the order the statute sets, place it as a supplement, a food, a cosmetic or a drug, and show where acting in the wrong order closes a route.Run the decision tree → All stages · Demonstration 4One curcumin program, eight connected decisionsA hypothetical turmeric extract followed from the intake screen to a supply agreement, with published data at each stage, six rejected alternatives and the constraints each stage hands to the next.Follow the program →Extraction
How extraction choices are compared before a process is fixed.
Open the demonstration → Stages 4 and 7Consistency
How lot-to-lot consistency is judged before a specification is set or a process is transferred.
Open the demonstration → Stage 5Solubility
Why the solubility question comes before any carrier is chosen.
Open the demonstration →05 · How value would build
Fees first, then owned ingredients, own products and licenses; drug candidates only through partners
The same engine would earn in three ways over time. Each passes its own gate, and success in one does not imply the next.
Development and testing fees
Stages 0 to 7 offered as full programs or single services, each ending in a document the client receives under contract terms.
Owned ingredients, own products, licenses and supply
Ingredients EUTECNIQ designs in their final format, used in its own products and supplied under quality agreements, and processes or formulations licensed where they are protectable. A naturally occurring constituent is not patent-eligible merely because it has been isolated; compositions, processes, formulations and methods of use can be.
Selected drug candidates, through partners
FDA has approved botanical drugs: it lists four approved under the NDA and BLA pathways, from 2006 to 2023. A candidate would go to a spin-off, licensee or buyer with drug development capacity; EUTECNIQ would not sponsor or manufacture drugs.
Proposed capabilityA business model, not a forecast: no revenue, customer, license or drug program exists. Sources: Myriad (2013); FDA CDER (September 3, 2026); Ther Innov Regul Sci 2025.
06 · What a stage result does not prove
Eight results that are easy to overstate
Each stage report would name the claim its data support and the claim they do not.
| Stage | What the result shows | What it does not show |
|---|---|---|
| 1 | A model prediction | A measured result |
| 2 | A supplier’s certificate of analysis | An identity test |
| 3 | Extraction yield | Purity |
| 5 | Higher solubility or dispersibility | Higher absorption |
| 5 | In vitro bioaccessibility | Systemic bioavailability |
| 6 | Stability testing | A validated shelf life |
| 6 | An NDI notification | FDA approval |
| 7 | Laboratory feasibility | Commercial demonstration |
07 · Start at intake
Bring a candidate, a material or a process that has stalled
Describe the material, the intended use and the market. The first conversation would be the feasibility screen: whether a lawful route exists and what its evidence would cost.
Sources
Every rule and number on this page traces to these sources
Regulations, guidance, standards and peer-reviewed studies, as cited on the linked EUTECNIQ pages. Each was reviewed on the date given with its citation. Summaries are not legal advice.
Regulation and FDA documents
- 21 U.S.C. 321(g)(1) and 321(ff), including (ff)(3)(B). U.S. Code (Cornell LII). law.cornell.edu/uscode/text/21/321
- 21 CFR 101.93, certain types of statements for dietary supplements. eCFR, current to Oct 21, 2026. ecfr.gov/current/title-21/chapter-I/subchapter-B/part-101/subpart-F/section-101.93
- 21 CFR Part 111, including 111.70 and 111.75. eCFR, current to Oct 21, 2026. ecfr.gov/current/title-21/chapter-I/subchapter-B/part-111
- 21 CFR 190.6, requirement for premarket notification. eCFR. ecfr.gov/current/title-21/chapter-I/subchapter-B/part-190/subpart-B/section-190.6
- 21 CFR Part 58, Good Laboratory Practice for Nonclinical Laboratory Studies (58.1, 58.3(e)). eCFR, up to date as of Oct 22, 2026. ecfr.gov/current/title-21/chapter-I/subchapter-A/part-58
- 21 CFR Parts 50 and 56. Protection of human subjects; institutional review boards. eCFR, current to Oct 21, 2026. ecfr.gov/current/title-21/chapter-I/subchapter-A/part-50
- 21 CFR Part 312, Investigational New Drug Application. eCFR. ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312
- 21 CFR Part 1, Subpart L, Foreign Supplier Verification Programs (1.511). eCFR. ecfr.gov/current/title-21/chapter-I/subchapter-A/part-1/subpart-L
- FDA warning letter 566205, DK Vitamins, Feb 5, 2019. fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dk-vitamins-566205-02052019
- Electronic Code of Federal Regulations. 21 CFR 184.1240, Carbon dioxide. Up to date as of October 23, 2026. ecfr.gov/current/title-21/section-184.1240
- FDA. NDI Notifications and Related Issues; Identity and Safety Information About the NDI. Guidance for industry, October 2026 (docket FDA-2025-D-6501), sections VII.1 and IX.4–6. fda.gov/media/195770/download
- U.S. FDA. Draft Guidance for Industry: Dietary Supplements: New Dietary Ingredient Notifications and Related Issues (revised draft, August 2016; October 2026 revision with Document History). Docket FDA-2011-D-0376. Draft, not for implementation. fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-new-dietary-ingredient-notifications-and-related-issues
- FDA CDER. What is a Botanical Drug? Updated Sep 3, 2026. fda.gov/about-fda/cder-offices-and-divisions/what-botanical-drug
- FDA. Frequently Asked Questions on Patents and Exclusivity. fda.gov/drugs/development-approval-process-drugs/frequently-asked-questions-patents-and-exclusivity
- Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013). law.cornell.edu/supremecourt/text/12-398
- U.S. Food and Drug Administration. Inspection observations: FY2019–FY2025 spreadsheets, Foods tab (Form 483 observations from FDA's electronic inspection tool), page content current as of December 16, 2025. Summed by 21 CFR Part 111 subpart. Retrieved October 24, 2026. fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/inspection-observations
Guidelines, compendia, standards and treaties
- FDA. Q2(R2) Validation of Analytical Procedures. Final guidance, March 2024. fda.gov/regulatory-information/search-fda-guidance-documents/q2r2-validation-analytical-procedures
- ICH Q1A(R2) Stability Testing of New Drug Substances and Products, Step 4 version dated 6 February 2003 (sections 2.1.6 and 2.2.6 testing frequency; 2.1.7.1, 2.1.7.2, 2.2.7.1 storage conditions; 2.2.3 selection of batches). database.ich.org/sites/default/files/Q1A%28R2%29%20Guideline.pdf
- ICH Q8(R2) Pharmaceutical Development, Step 4 version dated August 2009 (glossary; Part II sections 2.3–2.5; Appendices 1 and 2). database.ich.org/sites/default/files/Q8%28R2%29%20Guideline.pdf
- ICH Q9(R1) Quality Risk Management, adopted 18 January 2023 (section 3 principles; glossary; Annex I.1 and I.5). database.ich.org/sites/default/files/ICH_Q9%28R1%29_Guideline_Step4_2022_1219.pdf
- ICH Q10 Pharmaceutical Quality System, Step 4 version dated 4 June 2008 (sections 1.6 and 3.2). database.ich.org/sites/default/files/Q10%20Guideline.pdf
- ICH Q5E Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process. Step 4, 18 November 2004. database.ich.org/sites/default/files/Q5E%20Guideline.pdf
- ICH Q3C(R9) Guideline on impurities: guideline for residual solvents, Step 5. EMA/CHMP/ICH/82260/2006, April 5, 2024 (Tables 1–3; Part VI, 2-MTHF, CPME and TBA). ema.europa.eu/en/documents/scientific-guideline/ich-q3c-r9-guideline-impurities-guideline-residual-solvents-step-5_en.pdf
- EMA HMPC. Reflection paper on the level of purification of extracts to be considered as herbal preparations. EMA/HMPC/186645/2008, adopted Sep 16, 2010. ema.europa.eu/en/documents/scientific-guideline/reflection-paper-level-purification-extracts-be-considered-herbal-preparations_en.pdf
- EMA Committee on Herbal Medicinal Products. Reflection paper on markers used for quantitative and qualitative analysis of herbal medicinal products and traditional herbal medicinal products. EMEA/HMPC/253629/2007, 15 July 2008. ema.europa.eu/en/documents/scientific-guideline/reflection-paper-markers-used-quantitative-qualitative-analysis-herbal-medicinal-products_en.pdf
- USP Herbal Medicines Compendium. General chapters (⟨561⟩, ⟨563⟩, ⟨565⟩). hmc.usp.org/about/general-chapters
- United States Pharmacopeia. ⟨2040⟩ Disintegration and Dissolution of Dietary Supplements. doi.usp.org/USPNF/USPNF_M99970_04_01.html
- ISO 22412:2025. Particle size analysis — Dynamic light scattering (DLS). Edition 3, September 2025 (replaces ISO 22412:2017). iso.org/standard/85505.html
- ISO 13320:2020. Particle size analysis — Laser diffraction methods. scc-ccn.ca/standardsdb/standards/8168933
- Pappa H. USP general chapters on validation, verification and transfer of analytical procedures (<1225>, <1226>, <1224>, <1220>, <1210>). Presentation, Association for Accessible Medicines. accessiblemeds.org/wp-content/uploads/2024/09/Horacio-Pappa-1.pdf
- EFSA Scientific Committee; More SJ, Bampidis V, Benford D, et al. Guidance on the use of the benchmark dose approach in risk assessment. EFSA Journal. 2022;20(10):e07584. doi.org/10.2903/j.efsa.2022.7584
- EFSA Scientific Committee. Guidance on the use of the Threshold of Toxicological Concern approach in food safety assessment. EFSA Journal 2019;17(6):5708. doi.org/10.2903/j.efsa.2019.5708
- CITES. What is CITES? cites.org/eng/disc/what.php
- Convention on Biological Diversity. About the Nagoya Protocol (adopted Oct 29, 2010; in force Oct 12, 2014). cbd.int/abs/about
Published studies and data
- Royal Botanic Gardens, Kew. State of the World's Plants and Fungi 2020. doi.org/10.34885/172
- Wang M, et al. Sharing and community curation of mass spectrometry data with Global Natural Products Social Molecular Networking. Nat Biotechnol 2016;34:828–837. doi.org/10.1038/nbt.3597
- Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46(1-3):3–26. doi.org/10.1016/s0169-409x(00)00129-0
- Raclariu AC, Heinrich M, Ichim MC, de Boer H. Benefits and limitations of DNA barcoding and metabarcoding in herbal product authentication. Phytochem Anal. 2018;29(2):123–128. doi.org/10.1002/pca.2732
- Perini M, Pianezze S, Ziller L, Larcher R, Pace R. Stable isotope ratio analysis for the authentication of natural antioxidant curcuminoids from Curcuma longa (turmeric). Antioxidants. 2023;12(2):498. Open access (PMC9952763); Table 1 values used in the 02 Ingredient Fingerprint figure (full text read October 31, 2026). doi.org/10.3390/antiox12020498
- Thompson JD, Chalchat JC, Michet A, Linhart YB, Ehlers B. Qualitative and quantitative variation in monoterpene co-occurrence and composition in the essential oil of Thymus vulgaris chemotypes. J Chem Ecol. 2003;29(4):859–880. doi.org/10.1023/A:1022927615442
- Pouton CW. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur J Pharm Sci. 2000;11 Suppl 2:S93–S98. doi.org/10.1016/S0928-0987(00)00167-6
- Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci. 2006;29(3–4):278–287. doi.org/10.1016/j.ejps.2006.04.016
- Brodkorb A, Egger L, Alminger M, et al. INFOGEST static in vitro simulation of gastrointestinal food digestion. Nat Protoc. 2019;14(4):991–1014. doi.org/10.1038/s41596-018-0119-1
- Meigs L, Smirnova L, Rovida C, Leist M, Hartung T. Animal testing and its alternatives – the most important omics is economics. ALTEX 2018;35(3):275–305, Table 3. doi.org/10.14573/altex.1807041
- Park JK, Lee D, Rui L, Gao X, Furness MS, Wu C. Analysis of regulatory botanical submission profile for cancer management from the U.S. FDA perspectives. Ther Innov Regul Sci. 2025;59(5):1129–1137. doi:10.1007/s43441-025-00786-y pmc.ncbi.nlm.nih.gov/articles/PMC12446141/
- Thybo P, Hovgaard L, Lindeløv JS, Brask A, Andersen SK. Scaling up the spray drying process from pilot to production scale using an atomized droplet size criterion. Pharm Res. 2008;25(7):1610–1620. doi.org/10.1007/s11095-008-9565-8
- Yu LX, Amidon G, Khan MA, Hoag SW, Polli J, Raju GK, Woodcock J. Understanding pharmaceutical quality by design. AAPS J. 2014;16(4):771–783 (control strategy levels; CMA definition). doi.org/10.1208/s12248-014-9598-3
- Pan X, Li Y, Wu Z, Zhang Q, Zheng Z, Shi X, Qiao Y. A online NIR sensor for the pilot-scale extraction process in Fructus aurantii coupled with single and ensemble methods. Sensors. 2015;15(4):8749–8763. doi.org/10.3390/s150408749
Health information notice. These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease, and nothing here is medical advice.
Read the full notice
The information is for general education only. It does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed. Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.